IL-12 is thought to induce a cytokine cascade with antiangiogenic effects mediated by IFN-g and angiostatic CXCR3 chemokine ligands. Naked DNA intramuscular injection of an expression vector plasmid producing IL-12 resulted in significant, well-tolerated elevation of serum IL-12 levels. Injection of the IL-12 plasmid at least 2 days, and up to 20 days, before subcutaneous injection of matrigel with angiogenic factors resulted in strong prevention of angiogenesis in both C57/bl and nude mice. A single injection of the IL-12 plasmid contemporarily with the matrigel or 2 days after resulted in partial, statistically not significant, inhibition. Control plasmid injection did not affect either angiogenesis or angiogenesis inhibition by IL-12 protein in vivo. Angiogenesis inhibition was observed in NK cell-depleted C57/bl and nude mice as well as in IFN-g À/À and CXCR3 À/À knockout mice, indicating that NK-and/or T-cell-initiated IFN-gchemokine cascades were not involved in the angiogenesis inhibition observed in vivo. Finally, IL-12 plasmid DNA gene transfer significantly prevented the growth and vascularization of highly angiogenic KS-Imm Kaposi's sarcoma and TS/ A murine mammary carcinoma tumors in nude and/or syngeneic mice. These data suggest that a preventive gene therapy approach using antiangiogenic cytokines can effectively inhibit tumor angiogenesis and KS, representing an example of angioimmunoprevention.
Introduction
Tumor angiogenesis is necessary for tumor growth and metastatic dissemination. 1, 2 During the neovascularization process, endothelial cells migrate, proliferate and differentiate to organize new vessels in response to growth factors and cytokines produced by inflammatory and tumor cells. Current studies suggest that if the vascularization of tumors can be blocked, the tumor mass will be limited in size. Further, data suggest that the acquisition of the angiogenic phenotype (the 'angiogenic switch') coincides with conversion to malignancy. 3 Prevention of this switch could keep tumors dormant indefinitely. One approach to this is 'angioprevention', the use of chemoprevention drugs with low or no toxicity that target angiogenesis that we recently proposed. 4 These drugs that selectively inhibit or prevent angiogenesis may offer a cancer treatment modality that is complementary to drugs that target tumor cells directly.
IL-12 is a disulfide-linked heterodimeric cytokine composed of a light chain (p35) and a heavy chain (p40), 5 produced mainly by antigen-presenting cells (APCs). It binds to receptors on T cells and NK cells, activates them, and promotes the induction of the T helper type 1 (Th1) response in vitro as well as in vivo. 6, 7 In animal models, IL-12 has been shown to induce strong direct antitumor immunity by activating NK and CD8 þ T cells, with CD8 þ -dependent tumor regression and rejection. 7 Recent studies in vivo have shown that a naked DNA approach to IL-12 delivery produces longterm antimetastatic effects, again mediated largely by NK and partially by CD8 þ T cells. [8] [9] [10] Thus IL-12 appears to generate potent antitumor immunity in many model systems; unfortunately, this sort of specific CD8 þ tumor CTL responses and NK cell-mediated tumor rejection so far have been difficult to elicit in the clinic effectively. 11 IL-12 has also been shown to harbor an antiangiogenic activity 12, 13 that appears to largely mediate tumor suppression in some models. 14 The mechanism by which IL-12 inhibits angiogenesis is not fully known. Several studies indicated that it is mediated indirectly through triggering of NK and T-cell secretion of IFN-g and subsequent induction of the angiostatic chemokines such as CXCL10. 15, 16 However, other studies have proposed IFN-g-independent mechanisms, requiring direct lymphocyte-endothelial cell interactions 13, 17 or resetting of the genetic program of tumor cells to a less angiogenic phenotytpe. 18 Cytokines with antiangiogenic activity are promising agents for tumor therapy due to their activity at low concentrations. However, therapy with recombinant IL-12 has been associated with significant toxicity, indicating that alternative delivery systems focusing on antiangiogenic activity, while avoiding toxicity, should be developed. Gene transfer represents a promising strategy for prevention and therapy of cancer, and this is particularly true for angiogenesis inhibitors that must be administered chronically. The ideal gene products for gene therapy should exhibit high biological potency at low levels of expression, a characteristic of cytokines, and should avoid development of tumor resistance, a characteristic of antiangiogenic factors.
Here we used a gene therapy approach using a naked DNA expression vector for IL-12 to obtain long-term systemic IL-12 expression and demonstrate that this is sufficient to inhibit angiogenesis and tumor growth in vivo. Angiogenesis in vivo was assessed using the subcutaneous matrigel sponge assay. The effects on angiogenic tumor growth were determined using xenografts of either a human Kaposi's sarcoma cell line in nude mice, a tumor type for which clinical trials with IL-12 are underway, 19 or with murine TS/A mammary carcinoma cells in both nude and immunocompetent syngeneic animals. Effective inhibition of angiogenesis required administration of the IL-12 plasmid DNA at least 2 days prior to the angiogenic stimulus (prevention), as administration at the same time or after the angiogenic stimulus (intervention) resulted in partial and not significant inhibition. No overt toxicity was observed using this delivery approach. Depletion of T and/or NK cells by using nude athymic mice and anti-GM asialo antibodies did not affect the antiangiogenic activity of IL-12 gene transfer. Further, IL-12 inhibited angiogenesis even in IFN-g and CXCR3 knockout mice, indicating that the inhibition of angiogenesis observed did not require the IFN-g-induced angiostatic chemokine pathway.
The suppression of tumor growth observed in this model can be ascribed to inhibition of the early development of the tumor vasculature. We suggest that IL-12 could be used in both an angiopreventive 4 setting and in an immunopreventive approach, 13, 20 particularly suited for patients with medium to high risk for tumor development.
Results

Prevention of angiogenesis in vivo by IL-12 gene therapy
The previous observations that naked DNA IL-12 gene transfer was sufficient to obtain antimetastatic effects 9 suggested that this approach to IL-12 delivery may also produce antiangiogenic effects in vivo. In vivo angiogenesis was examined using the murine matrigel sponge model as previously described, 21 using a potent angiogenic cocktail of VEGF and TNFa, which produced an intense angiogenic reaction in vivo (Figure 1a ). We first verified whether IL-12 protein was able to inhibit angiogenesis induced by the VEGF/TNFa cocktail. Inclusion of 10 ng/ml of IL-12 protein in the matrigel along with these angiogenic factors resulted in significant inhibition of the vascularization of the gel in response to the angiogenic stimulus ( Figure 1a) .
Previous studies indicated that intramuscular (i.m.) injection of naked DNA of this plasmid resulted in longterm IL-12 production. 9, 22 In agreement with these observations, i.m. injection 20 days prior to, or 20 days and 2 days prior to initiation of the angiogenesis assay, resulted in strong and significant angiogenesis inhibition (Figure 1b) . These data indicate that the IL-12 plasmid effect in vivo was relatively long-lasting and equivalent or superior to that of IL-12 protein directly added to the gels. Injection of the plasmid without IL-12 insert had no effect on angiogenesis. Interestingly, injection of the IL-12 expression plasmid 2 days prior to and on the same day as injection of the matrigel plugs also produced a strong and significant inhibition of angiogenesis (Figure 1b) . This procedure produced a low, but clearly significant, increase in serum IL-12 protein levels in the IL-12 plasmid-treated animals (Figure 1c ), demonstrating effective tissue transduction and protein production. A single injection 2 days prior to matrigel injection was also sufficient to give a significant inhibition of angiogenesis. Histological analyses of the recovered gels indicated an intense cellular infiltrate accompanied by the formation of dilated, hemorrhagic vessels partially covered with an endothelium in the VEGF-and TNFa-containing gels in control animals (not shown). In contrast, in the IL-12 plasmid-treated animals there was little cellular infiltrate into the gels, and vessel formation was essentially absent (not shown). 
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Injection of the IL-12 plasmid at the same time as the injection of the matrigel plug (day 0) or 2 days after (day 2) only partially reduced angiogenesis, and inhibition was not statistically significant. These data indicate that at least 2 days were required after plasmid administration to obtain sufficient systemic IL-12 effects to prevent angiogenesis ( Figure 1b) .
NK or T cells are not required for the antiangiogenic effects of IL-12 plasmid gene transfer
To examine the role of NK and T cells in inhibition of angiogenesis, we investigated whether IL-12 plasmid therapy could inhibit angiogenesis in athymic nu/nu mice, which lack T cells, C57BL6 mice that were NK cell depleted by administration of the asialoGM antibody, and NK cell-depleted nu/nu mice. Depletion of NK cells in C57/bl mice had no effect either on the angiogenic reaction or on the extent of inhibition exerted by vaccination with the IL-12 expression plasmid ( Figure  2a ). Gene transfer of the IL-12 plasmid significantly inhibited angiogenesis induced by supernatants of Kaposi's sarcoma cells (KS-CM) in athymic nu/nu mice ( Figure 2b ), indicating that T cells alone were not the principal mediators of this activity. Finally, NK cell depletion in nu/nu mice also did not show significant alterations in the angiogenesis inhibition exerted by IL-12 gene transfer (Figure 2b ). Taken together, these data suggest that neither NK nor T cells were critical for the angiogenesis inhibitory activity of IL-12 gene transfer. It has been proposed that IFN-g produced by these cells after IL-12 stimulation may be the main mediator of these effects; however, NK and T cells were not required for the angiogenesis inhibition observed in this model, questioning the role of IFN-g.
IL-12 plasmid DNA inhibition of angiogenesis is independent of IFN-g and the CXCR3 ligands
To address directly whether IFN-g plays a role in angiogenesis inhibition by IL-12, the ability of IL-12 plasmid naked DNA gene transfer to inhibit angiogenesis was tested in IFN-g knockout mice on the Balb-c H2 d strain background. The VEGF/TNFa cocktail induced a clear, though less intense, angiogenic reaction in the control-and vector-injected animals, while angiogenesis was strongly and significantly inhibited in the IL-12 DNA-treated animals ( Figure 3a ). This demonstrates that the antiangiogenic effects of IL-12 were mediated through a pathway independent of IFN-g. These findings are consistent with those observed for the antimetastatic effects of IL-12. 9 We further investigated the role of NK or T cells tested in IFN-g knockout animals that were additionally depleted with either anti-asialo, anti-CD4 or anti-CD8 antibodies or a combination of all three. IL-12 plasmid naked DNA gene transfer consistently inhibited angiogenesis independently of NK and/or T-cell depletion in the IFN-g knockout animals as well (Figure 3b ), further indicating that these cells were not critical for the response observed.
Recent studies have suggested that class I interferons, which may be induced by exposure to plasmid CpG sequences, also result in upregulation of angiostatic chemokine CXCR3 ligands such as CXCL9 and CXCL10. 23, 24 To examine the role of this group of angiostatic chemokines, which are selective ligands for 
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, 25 the ability of IL-12 plasmid DNA gene transfer to inhibit angiogenesis was tested in CXCR3 À/À knockout mice. 26 The same naked DNA administration of the IL-12 plasmid again gave statistically significant inhibition of angiogenesis in these mice in vivo (Figure  3c ), demonstrating that these angiostatic chemokines are not the major mechanism mediating angiogenesis inhibition in this system.
Prevention of tumor growth by IL-12 gene transfer
To test the potential of naked DNA IL-12 gene transfer to inhibit vascular tumor growth, we first used KS-Imm cells, which rapidly form highly vascularized tumors when injected subcutaneously in nu/nu mice. Based on the above observations and previous studies, 9,22 the expression or control vectors were injected 11 and 2 days prior to injection of the KS-Imm cells and 7 days after KSImm cell injection. Tumor growth was followed for a total of 23 days, when the animals were killed. The injection of the vector alone had no effect on the growth of the KS-Imm tumors in vivo (Figure 4a ). In contrast, the growth of tumors in the IL-12 plasmid-treated animals was substantially reduced (Figure 4a) , with significant differences between the control and the IL-12-treated animals from day 18 to the end of the experiment (twoway ANOVA). The inhibition of tumor growth was associated with a statistically significant elevation in serum IL-12 levels that appeared to be constant over the duration of the experiment (Figure 4a, inset) . Serum IL-12 levels appeared to rise slightly, but not significantly, in the untreated animals, perhaps due to a host reaction to the tumor itself.
The ability of naked DNA IL-12 gene transfer to inhibit vascular tumor growth was confirmed using TS/A murine mammary carcinoma cells. These cells also rapidly formed vascularized tumors when injected subcutaneously in vivo; again treatment of the animals with the plasmid vector alone had no effect on tumor growth (Figure 4b ). Similar to that observed for human KS-Imm cells, naked DNA IL-12 gene transfer significantly inhibited TS/A tumor growth in nude animals with respect to controls (Figure 4b) . A similar pattern of significant tumor growth inhibition was found for TS/A tumors grown in syngeneic, immunocompetent Balb-c mice that were treated with the IL-12 expression vector (Figure 4c ). These data further indicate that the effect of low-level systemic IL-12 was largely mediated by angiogenesis inhibition, in the absence of induction of a specific immune response to these tumor cells.
Histological analysis of the tumors indicated extensive vascularization of the KS-Imm tumors grown in control animals. In contrast, the smaller tumors from IL-12 plasmid-treated animals showed a marked paucity of vascular structures ( Figure 5 ). The reduction of blood vessels in tumors from the IL-12-treated animals was confirmed by immunohistochemistry using anti-factor VIII antibodies to stain endothelial cells ( Figure 5 ).
Vessel density counts on tumor sections of the two groups of tumors showed a significantly (Po0.001, ANOVA) reduced vascular density in the IL-12-treated animals as compared to either control animal group (Figure 6a ). There was no statistical difference in vessel number between the control groups. The vessel densities correlated with the mean hemoglobin content of the tumor tissues, with the IL-12 plasmid DNA-treated animals showing significantly less hemoglobin (Po0.05, ANOVA) in the tumor tissue as compared to controls (Figure 6b ). Again there were no differences between the control groups.
Discussion
The cytokine IL-12 in addition to activating T and NK cells toward a TH1 phenotype has a strong angiostatic activity. 27, 28 Several studies have shown that IL-12 administration can induce tumor regression and rejection either alone or in combination with other immune stimuli or even antiangiogenic agents. While inhibition of angiogenesis has been observed, in most instances tumor rejection was associated with generation of a CD8 þ -mediated antitumor cell response. 29 induction has been suggested to also have a role in induction of antitumor CD8 þ responses, 30 other studies have indicated that the antitumor activity of IL-12 is not fully dependent on IFN-g. 31 Here we observed that IL-12 naked DNA gene transfer was equally effective in inhibiting angiogenesis in nude mice lacking T cells, NK-depleted mice and NK-depleted nude mice. This suggested that either IFN-g was produced by cells other than these cells or that IFN-g was not critical for the antiangiogenic effects in this model. In fact, angiogenesis inhibition by IL-12 plasmid DNA administration was also observed in IFN-g knockout mice, clearly indicating that IFN-g was not required. Previous studies indicated that the antiangiogenic effects of IL-12 in different model systems may be independent of IFN-g and require lymphocyte-endothelial cell contact. 17 We observed that IL-12 had no effect on endothelial cell proliferation or morphogenesis in vitro (data not shown), indicating that the antiangiogenic activity of IL-12 was not due to a direct effect on the endothelial cells. Further, our data using CXCR3
IFN-g
À/À knockout mice exclude CXCL10 (IP-10) and/or other CXCR3 ligands from having a dominant role in the inhibition of angiogenesis observed with plasmid IL-12.
It is of note that in previous reports syngeneic IL-12-engineered TS/A mammary adenocarcinoma cells showed minimal changes in their tumorigenicity and the deriving tumors displayed no significant changes in microvascular density with respect to wild-type tumors in IFN-g-deficient mice. 31 In contrast, the same IL-12-engineered cells were rejected by immunocompetent syngeneic mice, and antiangiogenic effects were shown to play an important role in this tumor model. 29 The apparent discrepancy observed by the use of plasmid IL-12 gene transfer, which also induced antiangiogenic activity in IFN-g knockout mice, may depend either on possible adjuvant effects exerted by the plasmid backbone itself through immune system stimulation by unmethylated CpG sequences, or to variability in the sensitivity of the different tumor models to the antiangiogenic effects of IL-12. Here we did not observe significant angiogenesis inhibition with the control plasmid vector DNA, nor did it increase the level of inhibition produced by IL-12 protein in the matrigel pellet (not shown). These data indicate that IL-12 synthesis was required for the angiostatic activity, and that interferons or other cytokines induced by CpG sequences alone were not sufficient to suppress angiogenesis in this model. Naked DNA IL-12 plasmid administration gave low but significantly elevated serum IL-12 levels that was constant over time and correlated with long-lasting effects in vivo. Recently a 'light' recombinant IL-12 schedule has been found to be effective in delaying mammary carcinogenesis in HER-2/neu transgenic mice, 32 although these doses were still higher than that tolerated in human studies. The constant, low levels of IL-12 produced by the naked DNA protocol employed here suggest that effective angiogenesis inhibition can be obtained without toxicity using a gene therapy approach. However, this required pretreatment at least 2 days prior to giving the angiogenic stimulus, implicating the induction of a molecular cascade was required for the antiangiogenic IL-12 effects. The antimetastatic effect of IL-12 also required administration of the IL-12 plasmid 
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close to that of endovenous injection of the tumor cells as the effect was completely lost if the plasmid followed tumor cell injection by more than 1 day. 9 Further, unlike most IL-12 studies, the antiangiogenic and tumor suppressive effects observed here were clearly independent of development of specific CD8 þ CTL. Transfection of poorly immunogenic, MHC class I negative tumor cells with an IL-12 expression vector alone was found to have little effect on tumor growth in nude mice in vivo, while a combination with an IL-15 expression vector gave a consistent local tumor rejection. 33 This effect was much greater than that observed with IL-15 alone, and appeared to be CTL independent, mediated by nonspecific innate immunity and NO release by macrophages in particular. Tumor cells transfected with IL-12 alone gave tumors with reduced vascularization, although this was not sufficient to produce a significant inhibition of tumor growth. Interestingly, rejection of IL-12/IL-15-transfected tumors was observed in NK-depleted nude mice, which did not show release of IFN-g in response to these tumors. 33 Finally, the IL-12 naked DNA plasmid administration approach utilized here produced slower tumor growth, but not tumor rejection, which was present even in immunocompromised animals, and this is consistent with a predominant angio-angiogenic activity rather than immunostimulatory activity.
Ongoing clinical studies by the group of R Yarchoan using IL-12 protein for treatment of Kaposi's sarcoma indicate a slow regression of the KS lesions, consistent with an antiangiogenic action, without undue toxicity of the IL-12 protein treatment. 19 Taken together, our data support that the concept of systemic delivery of IL-12 at low levels, possibly through a gene therapy approach, could provide potent suppression of angiogenesis and growth of highly angiogenic tumors such as Kaposi's sarcoma. Further, these data support the application of immunoprevention and angioprevention approaches for patients at elevated risk, possibly through IL-12 gene transfer.
Materials and methods
Materials. The pIRES-mu IL-12 vector used was described by Schultz et al, 9 with the expression of the two subunits of IL-12 cDNA (p40 and p35) directed by the human cytomegalovirus (CMV) immediate-early (IE-1) promoter/enhancer regions in the pVR1012 plasmid (VICAL, San Diego CA, USA). The pVR1012 plasmid alone without the IL-12 DNA was used as a control.
Angiogenesis assay. The Matrigel sponge model of angiogenesis was utilized as previously described. 34 Angiogenic growth factors were added to unpolymerized liquid matrigel at 41C. This suspension (final volume 600 ml) will slowly injected subcutaneously into the flank of mice where the matrigel polymerizes to form a solid gel. After 4 days, gels were recovered, weighed and either fixed in formalin and embedded in paraffin for histological examination or minced, diluted in water and the hemoglobin content measured with a Drabkin reagent kit (525, Sigma). The final concentration of hemoglobin was calculated from a standard calibration curve. In some experiments, 10 ng/ml IL-12 protein was also added to the gels. Different schedules of plasmid injection were used, including: (1) injections 2 days before and on the same day of injection of the matrigel plug, (2) injection 20 and 2 days prior to matrigel injection, (3) single injections either 20 days prior to, 2 days prior to or on the same day as injection of the matrigel sponge. For IL-12 naked DNA plasmid injection, 100 ml of plasmid DNA, at 1 mg/ml, was injected intramuscularly into both quadriceps of anesthetized animals, with 50 ml of plasmid injected in multiple points in the quadriceps to maximize plasmid DNA uptake.
Host animals utilized were male mice from either C57BL/6N immunocompetent, 6-week athymic (nu/nu, CD1 obtained from Charles River, Calco, LC, Italy), 8-to 10-week-old male IFN-g À/À mice on the BALB-c H2 d background (Jackson Laboratory, Barr Harbor, ME, USA) or CXCR3 knockout mice on the C57BL/6N background 26 kindly supplied by Prof. Craig Gerard, Harvard, MA, USA. All the animals were housed under specific pathogen-free conditions according to current European Community guidelines.
NK, CD4 or CD8 cell depletion. In vivo depletion experiments were performed by i.p. injection of either a rabbit anti-asialo GM1 antiserum (Wako Chemicals GmbH, Dusseldorf, Germany) (0.2 ml of a stock solution diluted 1/20), an anti-CD8 (24.3) rat mAb or an anti-CD4 (GK1.5) rat mAb, both from the ATCC (Rockville, MD) and used as 0.1 ml of a 5 0 Â concentrate, or i.p. injection of all three antibodies. Control animals received normal rabbit serum or an irrelevant rat mAb. The anti-asialo antibodies were administered 4 and 2 days prior to matrigel injection, the others at days À2, 0 and þ 2, in the same schedule and doses that have been previously described and demonstrated to inhibit effectively specific immune cell responses. 35 NK cell depletion was routinely confirmed by immunofluorescence and FACS analysis to verify NK cell depletion in splenocytes at the end of the experiment, where DX-5 anti-NK antibody staining demonstrated NK cell depletion ranging from 65 -to 92% in the different animal models utilized (C57BL/ 6N, nu/nu or IFN-g À/À mice).
IL-12 ELISA. Sera were prepared from blood samples obtained from eye sampling by incubation at RT for 1 h followed by a centrifugation at 10 000 rpm for 5 min. The IL-12 ELISA kit (R&D Systems Inc., Minneapolis, MN, USA) was used to detect the IL-12 levels in sera according to the manufacturer's instructions.
In vivo tumor growth
Kaposi's sarcoma tumor growth was obtained by injection of 5 Â 10 6 human immortalized Kaposi's sarcoma cells (KS-IMM) 36 suspended in liquid Matrigel in a final volume of 250 ml s.c. in the flanks of nude mice. Syngeneic BALB/c or nude mice were injected s.c. with 1 Â 10 5 murine TS/A cells as previously described. 35 Plasmids were injected intramuscularly as above 11 and 2 days before injection of the tumor cells, and repeated 7 days after tumor cell injection. Mice were weighed and tumor growth was monitored by measuring tumor size on alternate days. At the end of the experiment, mice were killed, the tumors recovered, weighed and processed for histological analyses (see below). In one experiment, the tumors were recovered after 23 days IL-12 gene transfer inhibition of angiogenesis M Morini et al and divided into two parts, one for measurement of hemoglobin content (as described above) and a portion for confirmation of vessel content by histological analysis. Blood samples for IL-12 detection were collected at regular intervals before and after tumor cell injection.
Histological analyses. Samples were fixed in formalin and paraffin embedded using standard procedures. In all, 4 mm sections were rehydrated and stained with either hemataoxylin and eosin or processed for immunohistochemistry by standard procedures. Rehydrated sections were blocked with irrelevant serum, followed by incubation with primary antibody, biotinylated secondary antibody and visualized with the UltraVision tissue detection system (Lab Vision, Freemont, CA, USA). Sections were then lightly counter-stained with hematoxylin and mounted in glycergel. The primary antibody used was a monoclonal anti-factor VIII (DAKO, Carpenteria, CA, USA) to highlight vessels. Parallel negative controls were irrelevant primary antibodies.
Vessel densities were estimated by counting the vessels in random fields selected for sections of several different tumors derived from animals that were either untreated, treated with the control plasmid or treated with the IL-12 expression vector plasmid. All the clearly visible vessels in the unit field were counted; the counts were performed blindly as to the origin of the tissue section.
